Cannabis Reduction and Functional Outcomes
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: CBT4CBT (Computerized Cognitive Behavioral Therapy), Motivational Interviewing, Contingency Management.
- Who it may be relevant to
- Registry conditions: Cannabis Use Disorder. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Prospective Changes in Patient-reported and Objective Functioning Following Reduction of Cannabis Use
Overview
This study evaluates the effects of cannabis use reduction among adults diagnosed with cannabis use disorder (CUD). Participants will undergo an 8-week intervention combining motivational interviewing, computerized cognitive behavioral therapy (CBT4CBT), and financial incentives for reduction in urinary cannabinoids. The study aims to assess improvements in cannabis-related problems, sleep, cognitive performance, CUD severity, and quality of life.
Interventions
- Behavioral CBT4CBT (Computerized Cognitive Behavioral Therapy)
Participants will receive one therapist-led motivational interviewing/goal setting session followed by 7 sessions of computerized CBT4CBT. - Behavioral Motivational Interviewing
Participants will receive one therapist-led motivational interviewing/goal setting session followed by 7 sessions of computerized CBT4CBT. - Behavioral Contingency Management
Patients will receive contingent reinforcers (financial incentives for reduction in urinary cannabinoids).
Primary outcome measures
- Cannabis-Related Problems [Time frame: Week 8 (end-of-treatment)]
Secondary outcome measures (9)
- Total minutes of sleep per night [Time frame: Week 8 (end-of-treatment)]
- Minutes of light sleep per night [Time frame: Week 8 (end-of-treatment)]
- Minutes of rapid eye movement (REM) sleep per night [Time frame: Week 8 (end-of-treatment)]
- Minutes of deep sleep per night [Time frame: Week 8 (end-of-treatment)]
- Sleep efficiency rating [Time frame: Week 8 (end-of-treatment)]
- Rey Auditory Verbal Learning Test (Verbal Memory) Age-Adjusted Standard Score [Time frame: Week 8 (end-of-treatment)]
- Face/Name Associative Memory Test (Visual Memory) Age-Adjusted Standard Score [Time frame: Week 8 (end-of-treatment)]
- Oral Symbol Digit Test Age-Adjusted Standard Score [Time frame: Week 8 (end-of-treatment)]
- Pattern Comparison Processing Speed Test (Processing Speed) Age-Adjusted Standard Score [Time frame: Week 8 (end-of-treatment)]
Eligibility criteria
Inclusion criteria
- Age 18+
- Urinary cannabinoid level ≥ 50 ng/mL
- DSM-5 diagnosis of CUD (mild, moderate, or severe)
- Willingness to attempt cannabis reduction
- Completion of Intake Visit
Exclusion criteria
- Serious medical/psychiatric conditions
- Pregnancy or breastfeeding
- Use of cannabis in past 30 days was for medical purposes only
- Discontinuation or reduction of cannabis use may exacerbate a pre-existing condition
- Cognitive or understanding difficulties, as evidenced by inability to pass informed consent quiz
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
United States · 1 center
- Medical University of South Carolina — Charleston
Identifiers
NCT: NCT07218471 · Pro00145652 · NIDA R01 DA062443